March 10, 2018

Autolus Announces Confidential Submission of Draft Registration Statement for Potential Initial Public Offering in the United States


London, 5 March 2018

Autolus Limited, a U.K.-based biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced the confidential submission of a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to a potential initial public offering of ordinary shares in the United States. The timing and the terms of this potential initial public offering have not yet been determined and are subject to market conditions and other factors.

This announcement is being made pursuant to and in accordance with Rule 135 under the U.S. Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

– Ends –

Media Contact

JW Communications
Julia Wilson
+44 (0)7818 430877


Stay Updated on the Latest News in Synthetic Biology

Subscribe to the Weekly SynBioBeta Digest


Stay updated on the latest news in synthetic biology

Subscribe to the SynBioBeta news digest